Participation in activities of daily life can be challenging for those with transthyretin amyloid cardiomyopathy (ATTR-CM), a restrictive cardiomyopathy produced by extracellular deposition of transthyretin. Geographic and racial healthcare disparities add to the burden of disease. Shared decision making and early detection with readily available noninvasive tests, among other strategies, are essential as therapy for ATTR-CM.
